14-day Premium Trial Subscription Try For FreeTry Free
$5.35
+0.350 (+7.00%)
At Close: Apr 23, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile
There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Golden Star

Ticker Date Change Price
LPLA Apr 19 1.64% $262.59
MLI Apr 19 9.87% $52.28
LNG Apr 17 1.33% $156.81
FCN Apr 16 2.58% $207.62
ELV Apr 16 5.12% $506.97
DXC Apr 08 1.39% $20.87
ITCI Apr 05 8.14% $68.44
AKR Apr 05 6.84% $16.53
NSIT Apr 04 0.350% $185.62
VSTS Apr 04 0.638% $18.82
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT